Oxurion N.V.

BRU • Healthcare • Biotechnology • Quote as of 10/30/2026

Company Profile

IndustryBiotechnology

SectorHealthcare

ExchangeBRU

Market Capitalization0.1856 mln

Float194 mln

Earnings Date04/03/2027

EPS

0.10

Marginal

P / E

0.01

Anomalous

Piotroski F-Score

3 / 9

Below average

Beneish M-Score

122

Highly suspicious

Relative Strength

63 / 100

Outperforming

Pre-Tax Margin

-297%

Severely loss-making

Business Description

Based in Leuven, Belgium, Oxurion NV is a medical research company focused on protecting the eyesight of people living with serious retinal conditions, such as age-related macular degeneration and geographic atrophy. Founded in 1991 and previously called ThromboGenics NV, the company works to bring new treatments to patients at risk of losing their vision.

Key Fundamentals

EPS0.10

P/E0.01

ROE26.23

RPS0.02

ROIC-18.29

ROA-84.78

Interest Cover-16.03

EBITDA, mln-2.40

EV / EBITDA-4.91

EV / EBIT-4.73

Revenue, mln1.15

EV / Revenue10.30

Quote Details

Last 0.0008

Change 0.0002 (33.33%)

Open 0.0008

Volume 20,320,212

Turnover 16,256

Average Volume 3,929,434

Financial Ratios

Pre-Tax Profit Margin-297

Current Ratio0.09

Price / Sales0.05

Financial Strength

Altman Z-Score-49.6

Piotroski F-Score 3 / 9

Beneish M-Score122

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	0%	53 / 100
1 Month	-42.86%	1 / 100
2 Months	-69.23%	0 / 100
6 Months	-80%	0 / 100
1 Year	-93.85%	0 / 100